EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Serum Pentosidine in Relation to Obesity in Patients with Type 2 Diabetes and Healthy Controls

Sandra Baumann iD, Lilian Sewing, Cyril Traechslin, Wilma Verhagen-Kamerbeek, Leticia Grize, Marius Kraenzlin, Christian Meier iD

Calcified Tissue International · 2025

DOI: 10.1007/s00223-024-01338-6 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Calcified Tissue International, 2025. Verfasst von Sandra Baumann und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Diabetes, Spital Emmental, Burgdorf, Switzerland. Hauptthemen laut MEDLINE: Arginine, Bone Density, Diabetes Mellitus, Type 2, Lysine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Schweizerischen Gesellschaft für Endokrinologie und Diabetologie, Roche Diagnostics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pentosidine (PEN), a surrogate marker of advanced glycation end-product formation, reflects increased non-enzymatic cross-linking in bone collagen, which is thought to be an important determinant of bone fragility in type 2 diabetes mellitus (T2DM). We aimed to investigate serum concentrations of PEN in patients with T2DM and controls without T2DM and to examine its relationship with bone parameters and metabolic state such as glycaemic control, insulin resistance and body weight. In a cross-sectional study-design, data from postmenopausal women and men with T2DM ( n = 110) and controls without T2DM ( n = 111) were evaluated. Serum PEN was measured using an ELISA-based assay (CSB-E09415h, Cusabio). In addition, biochemical markers of glucose metabolism and bone turnover markers were measured. Bone mineral density (BMD) was assessed by dual-energy X-ray absorptiometry. After adjustment for age, gender and body mass index (BMI), serum PEN was significantly higher in patients with T2DM compared to controls ( p = 0.02) and most prominently in women with T2DM ( p = 0.09). We found a strong association of serum PEN concentrations with BMI in the entire study population ( R = 0.43, p < 0.001) as well as in patients with T2DM ( R = 0.28, p < 0.01). While bone turnover markers were significantly decreased, and BMD increased in patients with T2DM, only weak or no associations were observed between these skeletal surrogate markers and serum PEN. We conclude that serum PEN is strongly associated with BMI with highest levels in obese women with T2DM. Adjustment for patient’s weight is needed when evaluating serum PEN levels in patients with T2DM. Clinical Trial Information: NCT02551315.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ArginineBone DensityDiabetes Mellitus, Type 2LysineObesityAgedFemaleHumansMaleMiddle AgedBiomarkersBody Mass IndexCross-Sectional Studies

Stichwörter der Autor:innen

Bone turnoverObesityPentosidineType 2 diabetes

Substanzen

ArginineBiomarkersLysinepentosidine

Autor:innen und Institutionen

  • Division of Endocrinology and Diabetes, Spital Emmental, Burgdorf, Switzerland.
  • Division of Endocrinology, Diabetes and Metabolism, University Hospital Basel, Aeschenvorstadt 57, 4051, Basel, Switzerland.
  • Swiss Tropical and Public Health Institute and University of Basel, Basel, Switzerland.
  • Endocrine Clinic and Laboratory, Basel, Switzerland.
  • Division of Endocrinology, Diabetes and Metabolism, University Hospital Basel, Aeschenvorstadt 57, 4051, Basel, Switzerland. christian.meier@unibas.ch.
  • Endocrine Clinic and Laboratory, Basel, Switzerland. christian.meier@unibas.ch.

ORCID-Profile: Sandra Baumann, Christian Meier

Förderung

  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
  • Schweizerischen Gesellschaft für Endokrinologie und Diabetologie
  • Roche Diagnostics
  • University of Basel

Zitieren

APA

Baumann, S., Sewing, L., Traechslin, C., Verhagen-Kamerbeek, W., Grize, L., Kraenzlin, M., & Meier, C. (2025). Serum Pentosidine in Relation to Obesity in Patients with Type 2 Diabetes and Healthy Controls. Calcified Tissue International. https://doi.org/10.1007/s00223-024-01338-6

Vancouver

Baumann S, Sewing L, Traechslin C, Verhagen-Kamerbeek W, Grize L, Kraenzlin M, et al. Serum Pentosidine in Relation to Obesity in Patients with Type 2 Diabetes and Healthy Controls. Calcified Tissue International. 2025. doi:10.1007/s00223-024-01338-6

BibTeX
@article{Baumann2025,
  author = {Baumann, Sandra and Sewing, Lilian and Traechslin, Cyril and Verhagen-Kamerbeek, Wilma and Grize, Leticia and Kraenzlin, Marius and Meier, Christian},
  title = {Serum Pentosidine in Relation to Obesity in Patients with Type 2 Diabetes and Healthy Controls},
  journal = {Calcified Tissue International},
  year = {2025},
  doi = {10.1007/s00223-024-01338-6}
}
Kostenlos starten →